Organizations Our Experts Have Worked For
We systematically remove “Avoidable Hurdles” so cell & gene therapies reach patients sooner.
Already 250+ CGT professionals are joining our expert network — spanning the full gene therapy value chain.
Anything that could have been avoided — if only you had known about it sooner.
The only truly unavoidable challenge in gene therapy is a brand-new biological discovery. Everything else — someone, somewhere, has already solved. Our expert network makes sure you know — before it costs you.
Public grants and non-dilutive capital opportunities you didn’t know existed — until the deadline passed.
Learn MoreDesign decisions that looked fine in the lab but caused efficiency, safety, or manufacturing problems later.
Learn MoreManual workflows, fragmented data, and communication gaps that silently drain your budget.
Learn MorePrograms that fail IND requirements or investor scrutiny because gaps were caught too late.
Learn MoreLab-scale methods that don’t translate to clinical production, forcing costly late-stage pivots.
Learn MoreDue diligence that missed critical technical risks, leading to poor decisions or portfolio losses.
Learn MoreWe combine field expert knowledge with AI to catch problems before they cost you.
Knowledge databases built and verified by field experts — not generic AI outputs. Expert-verified answers when the stakes are high.
We find and fix the operational cash leaks — replacing manual bottlenecks with smart automation.
Tell us who you are and what you need. We’ll point you to the right service.
"The deep dive into gene therapy production systems with Gene Therapy Consultancy gave us crucial clarity on choosing between stable cell lines and transient transfection for our program."
"The rapid technical assessment by GTC on Dual AAV plasmid system provided the clarity we needed to make a confident go/no-go decision, saving us significant time and resources."
"GTC's insights into viral vector QC, especially around qPCR/ddPCR, were incredibly practical and helped refine our testing strategy."
"The focused discussion with GTC on gene therapy approaches for acute ischemic stroke provided a much-needed expert perspective for our early research."
"GTC's rapid market insights for our new gene therapy-focused endonuclease product were invaluable for shaping our entry strategy."
"GTC's understanding of vector chromatography challenges helped us validate the value proposition for our process optimization software."
"A single hour provided a wealth of practical knowledge on gene therapy manufacturing instrumentation that we immediately put to use."
"Their expert perspective on gene therapy manufacturing nuances was instrumental in our due diligence process for a potential investment."
"The deep dive into gene therapy production systems with Gene Therapy Consultancy gave us crucial clarity on choosing between stable cell lines and transient transfection for our program."
"The rapid technical assessment by GTC on Dual AAV plasmid system provided the clarity we needed to make a confident go/no-go decision, saving us significant time and resources."
"GTC's insights into viral vector QC, especially around qPCR/ddPCR, were incredibly practical and helped refine our testing strategy."
"The focused discussion with GTC on gene therapy approaches for acute ischemic stroke provided a much-needed expert perspective for our early research."
"GTC's rapid market insights for our new gene therapy-focused endonuclease product were invaluable for shaping our entry strategy."
"GTC's understanding of vector chromatography challenges helped us validate the value proposition for our process optimization software."
"A single hour provided a wealth of practical knowledge on gene therapy manufacturing instrumentation that we immediately put to use."
"Their expert perspective on gene therapy manufacturing nuances was instrumental in our due diligence process for a potential investment."
Book a free discovery call or join our expert network to start collaborating.